Applied Filters
The battle for biotech drugs in India
India needs to focus more resources on evaluating applications for biologic drugs, while the biosimilar system needs to be tweaked, says Archana Shanker of Anand and Anand.
Zika vaccine: first bragging rights for India?
An Indian company is working on two approaches to creating a vaccine for the Zika virus, while several trademark applications have been filed for the term. Lucy Rana of SS Rana reports.
A hub of pharma innovation
Over the past few years there have been a number of IP developments in the pharma and biotech industries in Japan, including on patent term extension and product-by-process claims. Osamu Yamamoto of Yuasa and Hara provides a roundup.
Patent analysis: CRISPR technology in India
It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.
What the future holds for second medical use patents
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.
Taking shape: biosimilar rules in India
The Indian government has invited public comments on draft regulatory guidelines for biosimilars, while patent law in this area has still to take shape. Sameer Sah, Nisha Austine and Jahnvi Shah of Khaitan & Co report.
Avoiding the Actavis SPC trap
The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications.
Second medical use patents: why generics are in the dark
Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains.
Healthy farms, healthy planet
Intellectual property rights should be used to help valorise agricultural biodiversity and traditional knowledge for the benefit of the global population as well as small farming communities around the world, says Graham Dutfield of the University of Leeds.
IPR and biopharma patents: what the statistics show
Fewer IPR petitions are instituted against biotech and pharma patents, and there is a higher survival rate of instituted claims in final written decisions compared to all technical fields combined. Melissa Gibson and Ruben Munoz of Akin Gump analyse the statistics.
